Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy

New England Journal of Medicine

Volumn 379, Issue 11, 2018, Pages 1007-1016

  Maurer, Mathew S ^a,b,p   Schwartz, Jeffrey H ^c   Gundapaneni, Balarama ^d,f   Elliott, Perry M ^e   Merlini, Giampaolo ^f,j   Waddington Cruz, Marcia ^h   Kristen, Arnt V ^h,i   Grogan, Martha ^j   Witteles, Ronald ^k   Damy, Thibaud ^l   Drachman, Brian M ^m   Shah, Sanjiv J ⁿ   Hanna, Mazen ^o,p   Judge, Daniel P ^p   Barsdorf, Alexandra I ^q   Huber, Peter ^c   Patterson, Terrell A ^c   Riley, Steven ^c   Schumacher, Jennifer ^c   Stewart, Michelle ^c   Sultan, Marla B ^c   Rapezzi, Claudio ^g   more..

^a NewYork Presbyterian Hospital   (United States)

^b Columbia University Vagelos College of Physicians and Surgeons ^*  (United States)

^c PFIZER INC   (United States)

^d SYNEOS HEALTH   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j MAYO CLINIC   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l HENRI MONDOR HOSPITAL   (France)

^m PENN PRESBYTERIAN MEDICAL CENTER   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o LERNER RESEARCH INSTITUTE   (United States)

^p MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^q NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAFAMIDIS; BENZOXAZOLE DERIVATIVE; TRANSTHYRETIN;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; ATTR AMYLOIDOSIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HOSPITALIZATION; HUMAN; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE OVERALL SUMMARY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; URINARY TRACT INFECTION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHY; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; FAMILIAL AMYLOID POLYNEUROPATHY; HEART FAILURE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; WALK TEST;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; CARDIOMYOPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREALBUMIN; QUALITY OF LIFE; SURVIVAL ANALYSIS; WALK TEST;

EID: 85053189041     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1805689     Document Type: Article

References (34)

1. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
2. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300.
3. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016;68:161-72.
4. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133: 2404-12.
5. Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016; 1:880-9.
6. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.
7. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87.
8. Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 2016; 37:1826-34.
9. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014-20.
10. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2017 October 18 (Epub ahead of print).
11. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 1978;121:339-56.
12. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995;268:1039-41.
13. Colon W, Kelly JW. Partial denatur-ation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654-60.
14. Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 2015;20:163-78.
15. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001;293: 2459-62.
16. Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 2016;5:1-25.
17. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015;8:519-26.
18. Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis. Circ Heart Fail 2018;11(4):e004769.
19. Maurer MS, Elliott P, Merlini G, et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail 2017;10(6):e003815.
20. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
21. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35:1245-55.
22. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999;18: 1341-54.
23. Wolfinger RD. An example of using mixed models and PROC MIXED for longitudinal data. J Biopharm Stat 1997;7: 481-500.
24. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012;33:176-82.
25. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785-92.
26. Groenning BA, Nilsson JC, Sonder-gaard L, Fritz-Hansen T, Larsson HB, Hil-debrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-80.
27. Solomon SD, Foster E, Bourgoun M, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter Automatic Defibrillator Implantation Trial: cardiac resynchronization therapy. Circulation 2010;122:985-92.
28. Konstam MA, Rousseau MF, Kronen-berg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
29. Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH. Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy. Clin Med Insights Cardiol 2017;11: 1179546817730322.
30. Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 2017; 24:30-6.
31. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
32. 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging 2017;10: 713-4.
33. Glaudemans AW, van Rheenen RW, van den Berg MP, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35-44.
34. Galat A, Rosso J, Guellich A, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210-20.